## Supplementary information 2

## Search strategies

Table 1. MEDLINE search strategy to identify studies on prognostic accuracy and clinical impact

|  |  |  |
| --- | --- | --- |
| Database searched: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily and Versions(R)  Database searched from inception through to 14 June 2019 | | |
| # | Terms | Hits |
| 1 | Crohn Disease/ | 37169 |
| 2 | Crohn\*.mp | 53162 |
| 3 | ((Crohn$ adj2 (disease or syndrome)) or regional enteritis).tw. | 42992 |
| 4 | Inflammatory bowel diseases/ | 20151 |
| 5 | IBD.mp. | 22462 |
| 6 | Inflammatory bowel disease\*.mp. | 48138 |
| 7 | or/1-6 | 84595 |
| 8 | CD8-Positive T-Lymphocytes/ | 34782 |
| 9 | CD8+ T cells.mp. | 34207 |
| 10 | CD8 Antigens/ | 8666 |
| 11 | CD8 antigens.mp. | 8793 |
| 12 | CD8\*.mp. | 107288 |
| 13 | CD 8\*.mp. | 1186 |
| 14 | T-Lymphocytes, Regulatory/ | 29558 |
| 15 | Regulatory t cells.mp. | 20593 |
| 16 | (PredictSure or PredictImmune).mp. | 0 |
| 17 | or/8-16 | 139456 |
| 18 | Antibodies/ | 97179 |
| 19 | antibod\*.mp. | 1121351 |
| 20 | glycan.mp. | 15625 |
| 21 | (antichitobioside carbohydrate antibod\* or ACCA or chitobioside).mp. | 383 |
| 22 | (antilaminaribioside carbohydrate antibod\* or ALCA or laminaribioside).mp. | 291 |
| 23 | (antimannobioside carbohydrate antibod\* or AMCA or mannobioside).mp. | 322 |
| 24 | (anti-Saccharomyces cerevisiae antibod\* or ASCA or gASCA or mannan).mp. | 4629 |
| 25 | (anti-laminarin carbohydrate antibod\* or anti-L or laminarin).mp. | 1458 |
| 26 | (neutrophil elastase degraded elastin or EL-NE).mp. | 7 |
| 27 | glycominds.mp. | 4 |
| 28 | (Crohn's disease prognosis test or IBDX).mp. | 1 |
| 29 | or/18-19 | 1121351 |
| 30 | or/20-28 | 22376 |
| 31 | 29 and 30 | 4882 |
| 32 | 7 and 17 | 1667 |
| 33 | 7 and 31 | 421 |
| 34 | 32 or 33 | 2078 |

Table 2. EMBASE search strategy to identify studies on prognostic accuracy and clinical impact

|  |  |  |
| --- | --- | --- |
| Database searched: EMBASE  Database searched from inception through to 14 June 2019 | | |
| # | Terms | Hits |
| 1 | Exp Crohn Disease/ | 83531 |
| 2 | Crohn\*.mp | 94568 |
| 3 | ((Crohn$ adj2 (disease or syndrome)) or regional enteritis).tw. | 68633 |
| 4 | Exp Inflammatory bowel disease/ | 134801 |
| 5 | IBD.mp. | 46227 |
| 6 | Inflammatory bowel disease\*.mp. | 79562 |
| 7 | or/1-6 | 168160 |
| 8 | Exp CD8+ T Lymphocyte/ | 58540 |
| 9 | CD8+ T cells.mp. | 51161 |
| 10 | Exp CD8 Antigen/ | 69304 |
| 11 | CD8 antigen\*.mp. | 69501 |
| 12 | CD8\*.mp. | 177082 |
| 13 | CD 8\*.mp. | 1822 |
| 14 | exp regulatory T lymphocyte/ | 60131 |
| 15 | Regulatory t cell\*.mp. | 38135 |
| 16 | (PredictSure or PredictImmune).mp. | 0 |
| 17 | or/8-16 | 226662 |
| 18 | Exp Antibody/ | 1137041 |
| 19 | antibod\*.mp. | 1355710 |
| 20 | Exp Glycan/ | 12642 |
| 21 | glycan.mp. | 23624 |
| 22 | (antichitobioside carbohydrate antibod\* or ACCA or chitobioside).mp. | 439 |
| 23 | (antilaminaribioside carbohydrate antibod\* or ALCA or laminaribioside).mp. | 442 |
| 24 | (antimannobioside carbohydrate antibod\* or AMCA or mannobioside).mp. | 438 |
| 25 | (anti-Saccharomyces cerevisiae antibod\* or ASCA or gASCA or mannan).mp. | 8703 |
| 26 | (anti-laminarin carbohydrate antibod\* or anti-L or laminarin).mp. | 1603 |
| 27 | (neutrophil elastase degraded elastin or EL-NE).mp. | 21 |
| 28 | glycominds.mp. | 28 |
| 29 | (Crohn's disease prognosis test or IBDX).mp. | 11 |
| 30 | or/18-19 | 1620205 |
| 31 | or/20-29 | 34509 |
| 32 | 30 and 31 | 8156 |
| 33 | 7 and 17 | 4850 |
| 34 | 7 and 32 | 885 |
| 35 | 33 or 34 | 5719 |

Table 3. CENTRAL and CDSR search strategy to identify studies on prognostic accuracy and clinical impact

|  |  |  |
| --- | --- | --- |
| Database searched: Central Register of Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews (CDSR)  Database searched from inception through to 14 June 2019 | | |
| # | Terms | Hits |
| 1 | Crohn:ti,ab,kw | 4482 |
| 2 | MeSH: [Inflammatory bowel diseases] explode all trees | 2889 |
| 3 | IBD:ti,ab,kw | 1738 |
| 4 | “Inflammatory bowel disease”:ti,ab,kw | 2650 |
| 5 | #1 or #2 or #3 or #4 | 7295 |
| 6 | MeSH: [CD8-Positive T-Lymphocytes] explode all trees | 641 |
| 7 | MeSH: [CD8 Antigens] explode all trees | 71 |
| 8 | “CD8 Positive T-Lymphocytes”:ti,ab,kw | 503 |
| 9 | “CD8”:ti,ab,kw | 4211 |
| 10 | MeSH: [T-Lymphocytes, Regulatory] explode all trees | 274 |
| 11 | “Regulatory t cells”:ti,ab,kw | 620 |
| 12 | PredictSure” or “PredictImmune:ti,ab,kw | 0 |
| 13 | #6 or #7 or #8 or #9 or #10 or #11 or #12 | 4910 |
| 14 | MeSH: [Antibodies] explode all trees | 21533 |
| 15 | antibod\*:ti,ab,kw | 38301 |
| 16 | MeSH: [Polysaccharides] explode all trees | 15185 |
| 17 | glycan:ti,ab,kw | 144 |
| 18 | “antichitobioside carbohydrate antibod\*” or ACCA or chitobioside:ti,ab,kw | 18 |
| 19 | “antilaminaribioside carbohydrate antibod\*” or ALCA or laminaribioside:ti,ab,kw | 6 |
| 20 | “antimannobioside carbohydrate antibod\*” or AMCA or mannobioside:ti,ab,kw | 37 |
| 21 | “anti-Saccharomyces cerevisiae antibod\*” or ASCA or gASCA or mannan:ti,ab,kw | 139 |
| 22 | “anti-laminarin carbohydrate antibod\*” or anti-L or laminarin:ti,ab,kw | 1694 |
| 23 | “neutrophil elastase degraded elastin” or EL-NE:ti,ab,kw | 12 |
| 24 | glycominds:ti,ab,kw | 0 |
| 25 | “Crohn's disease prognosis test” or IBDX:ti,ab,kw | 0 |
| 26 | #14 or #15 | 44459 |
| 27 | #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 | 17149 |
| 28 | #26 and #27 | 914 |
| 29 | #5 and #13 | 38 |
| 30 | #5 and #28 | 14 |
| 31 | #29 or #30 | 52 |

Table 4. EMBASE search strategy to identify economic evaluations

|  |  |  |
| --- | --- | --- |
| Embase <1996 to 2019 Week 22>  Date of search 07/06/2019 | | |
| # | Terms | Hits |
| 1 | Crohn disease/ | 69892 |
| 2 | Crohn\*.mp. | 81047 |
| 3 | ((Crohn$ adj2 (disease or syndrome)) or regional enteritis).tw. | 58806 |
| 4 | inflammatory bowel disease/ | 26886 |
| 5 | IBD.mp. | 45145 |
| 6 | Inflammatory bowel disease\*.mp. | 73947 |
| 7 | or/1-6 | 126526 |
| 8 | CD8-Positive T-Lymphocyte/ | 58180 |
| 9 | CD8+ T cells.mp. | 48481 |
| 10 | CD8 Antigen/ | 62068 |
| 11 | (CD8 antigen\* or CD 8 antigen\*).mp. | 62126 |
| 12 | CD8\*.mp. | 161485 |
| 13 | CD 8\*.mp. | 1596 |
| 14 | regulatory T lymphocyte/ | 58360 |
| 15 | Regulatory t cells.mp. | 32962 |
| 16 | (PredictSure or PredictImmune).mp. | 0 |
| 17 | or/8-16 | 208245 |
| 18 | antibody/ | 154965 |
| 19 | antibod\*.mp. | 962533 |
| 20 | glycan.mp. | 21832 |
| 21 | (Antichitobioside carbohydrate antibod\* or ACCA or chitobioside).mp. | 405 |
| 22 | (antilaminaribioside carbohydrate antibod\* or ALCA or laminaribioside).mp. | 348 |
| 23 | (antimannobioside carbohydrate antibod\* or AMCA or mannobioside).mp. | 313 |
| 24 | (anti-Saccharomyces cerevisiae antibod\* or ASCA or gASCA or mannan).mp. | 7087 |
| 25 | (anti-laminarin carbohydrate antibod\* or anti-L or laminarin).mp. | 1201 |
| 26 | (neutrophil elastase degraded elastin or EL-NE).mp. | 20 |
| 27 | glycominds.mp. | 28 |
| 28 | (Crohn's disease prognosis test or IBDX).mp. | 11 |
| 29 | 18 or 19 | 962533 |
| 30 | or/20-28 | 30472 |
| 31 | 29 and 30 | 7021 |
| 32 | 7 and 31 | 839 |
| 33 | 7 and 17 | 4336 |
| 34 | 32 or 33 | 5160 |
| 35 | prednisolone/ | 91187 |
| 36 | prednisone/ | 119609 |
| 37 | cortisone/ | 6431 |
| 38 | methylprednisolone/ | 72061 |
| 39 | hydrocortisone/ | 80947 |
| 40 | (corticosteroid or prednisolone or prednisone or methylprednisolone or hydrocortisone or budesonide).ti,ab. | 133365 |
| 41 | mesalamine/ | 14425 |
| 42 | 6-mercaptopurine/ | 16507 |
| 43 | sulfasalazine/ | 18757 |
| 44 | (mesalamine or sulfasalazine or "5-aminosalicylic\*" or "5-aminosalicylate\*" or "5-asa" or 5aminosalicylic\* or 5aminosalicyclate\* or 5asa or pentasa or mesalazine or mesalamine or asacol or sulfasalazine\* or salazopyrin\* or salazosulfapyridine\* or asulfidine\* or azulfadine\* or azulfidine\*).ti,ab. | 11513 |
| 45 | azathioprine/ | 67700 |
| 46 | methotrexate/ | 130108 |
| 47 | (immunosuppressant or immunomodulator or mercaptopurine or methotrexate or amethopterin or Otrexup or Rasuvo or Rheumatrex or Trexall or Maxtrex or Nordimet or Zlatal or Methofill or Metoject or Jylamvo or azathioprine or Imuran or Azapress or thiopurine).ti,ab. | 83647 |
| 48 | ((biologic or biologics or tumour necrosis factor alpha or TNF) adj2 inhibitor\*).ti,ab. | 7815 |
| 49 | (infliximab or Remicade or Remsima or Inflectra or Zessly or Flixabi or adalimumab or Humira or Imraldi or Amgevita or Hulio or vedolizumab or Entyvio or ustekinumab or Stelara).ti,ab. | 34039 |
| 50 | top-down.mp. | 14798 |
| 51 | top down.mp. | 14798 |
| 52 | step-up.mp. | 3588 |
| 53 | step up.mp. | 3588 |
| 54 | or/35-50 | 548227 |
| 55 | 7 and 54 | 35020 |
| 56 | economics/ | 153443 |
| 57 | "health care cost"/ or "cost"/ or "drug cost"/ or "hospital running cost"/ or "hospital cost"/ or "hospitalization cost"/ or "nursing cost"/ | 267442 |
| 58 | "cost utility analysis"/ or "cost benefit analysis"/ or "cost effectiveness analysis"/ | 195011 |
| 59 | exp health economics/ | 672653 |
| 60 | budget/ | 23702 |
| 61 | budget\*.ti,ab,kw. | 29555 |
| 62 | (economic\* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\* or pharmaco-economic\* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti,kw. | 214226 |
| 63 | (economic\* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\* or pharmaco-economic\* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2 | 330337 |
| 64 | (cost\* adj2 (effective\* or utilit\* or benefit\* or minimi\* or analy\* or outcome or outcomes)).ab,kw. | 191330 |
| 65 | (value adj2 (money or monetary)).ti,ab,kw. | 2780 |
| 66 | statistical model/ | 149074 |
| 67 | economic model\*.ab,kw. | 4233 |
| 68 | probability/ | 85320 |
| 69 | Monte Carlo method/ | 35702 |
| 70 | monte carlo.ti,ab,kw. | 41897 |
| 71 | decision theory/ | 1327 |
| 72 | "decision tree"/ | 10402 |
| 73 | Markov chain/ or hidden Markov model/ | 6939 |
| 74 | markov.ti,ab,kw. | 25713 |
| 75 | (decision\* adj2 (tree\* or analy\* or model\*)).ti,ab,kw. | 28032 |
| 76 | or/56-75 | 1280505 |
| 77 | 7 and 76 | 6583 |
| 78 | 34 and 76 | 84 |
| 79 | 54 and 77 | 2391 |
| 80 | letter.pt. | 772802 |
| 81 | editorial.pt. | 512984 |
| 82 | note.pt. | 648565 |
| 83 | 80 or 81 or 82 | 1934351 |
| 84 | 78 not 83 | 84 |
| 85 | 79 not 83 | 2235 |
| 86 | limit 84 to human | 79 |
| 87 | limit 85 to human | 2150 |

Table 5. MEDLINE search strategy to identify economic evaluations

|  |  |  |
| --- | --- | --- |
| Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to June 04, 2019>  Date of search 07/06/2019 | | |
| # | Terms | Hits |
| 1 | Crohn Disease/ | 37141 |
| 2 | Crohn\*.mp. | 53094 |
| 3 | ((Crohn$ adj2 (disease or syndrome)) or regional enteritis).tw. | 42937 |
| 4 | Inflammatory bowel diseases/ | 20114 |
| 5 | IBD.mp. | 22412 |
| 6 | Inflammatory bowel disease\*.mp. | 48052 |
| 7 | or/1-6 | 84477 |
| 8 | CD8-Positive T-Lymphocytes/ | 34762 |
| 9 | CD8+ T cells.mp. | 34163 |
| 10 | CD8 Antigens/ | 8663 |
| 11 | (CD8 antigen\* or CD 8 antigen\*).mp. | 8934 |
| 12 | CD8\*.mp. | 107197 |
| 13 | CD 8\*.mp. | 1184 |
| 14 | T-Lymphocytes, Regulatory/ | 29536 |
| 15 | Regulatory t cells.mp. | 20560 |
| 16 | (PredictSure or PredictImmune).mp. | 0 |
| 17 | or/8-16 | 139329 |
| 18 | Antibodies/ | 97155 |
| 19 | antibod\*.mp. | 1120813 |
| 20 | glycan.mp. (15595) | 15595 |
| 21 | (Antichitobioside carbohydrate antibod\* or ACCA or chitobioside).mp. | 381 |
| 22 | (antilaminaribioside carbohydrate antibod\* or ALCA or laminaribioside).mp. | 291 |
| 23 | (antimannobioside carbohydrate antibod\* or AMCA or mannobioside).mp. | 321 |
| 24 | (anti-Saccharomyces cerevisiae antibod\* or ASCA or gASCA or mannan).mp. | 4624 |
| 25 | (anti-laminarin carbohydrate antibod\* or anti-L or laminarin).mp. | 1457 |
| 26 | (neutrophil elastase degraded elastin or EL-NE).mp. | 7 |
| 27 | glycominds.mp. | 4 |
| 28 | (Crohn's disease prognosis test or IBDX).mp. | 1 |
| 29 | 18 or 19 | 1120813 |
| 30 | or/20-28 | 22337 |
| 31 | 29 and 30 | 4877 |
| 32 | 7 and 17 | 1667 |
| 33 | 7 and 31 | 421 |
| 34 | 32 or 33 | 2078 |
| 35 | prednisolone/ | 32048 |
| 36 | prednisone/ | 38452 |
| 37 | cortisone/ | 19548 |
| 38 | methylprednisolone/ | 18301 |
| 39 | hydrocortisone/ | 70258 |
| 40 | (corticosteroid or prednisolone or prednisone or methylprednisolone or hydrocortisone or budesonide).ti,ab. | 120312 |
| 41 | mesalamine/ | 3345 |
| 42 | sulfasalazine/ | 4014 |
| 43 | (mesalamine or sulfasalazine or "5-aminosalicylic\*" or "5-aminosalicylate\*" or "5-asa" or 5aminosalicylic\* or 5aminosalicyclate\* or 5asa or pentasa or mesalazine or mesalamine or asacol or sulfasalazine\* or salazopyrin\* or salazosulfapyridine\* or asulfidine\* or azulfadine\* or azulfidine\*).ti,ab. | 7655 |
| 44 | 6-mercaptopurine/ | 6144 |
| 45 | azathioprine/ | 14345 |
| 46 | methotrexate/ | 36645 |
| 47 | (immunosuppressant or immunomodulator or mercaptopurine or methotrexate or amethopterin or Otrexup or Rasuvo or Rheumatrex or Trexall or Maxtrex or Nordimet or Zlatal or Methofill or Metoject or Jylamvo or azathioprine or Imuran or Azapress or thiopurine).ti,ab. | 67759 |
| 48 | ((biologic or biologics or tumour necrosis factor alpha or TNF) adj2 inhibitor\*).ti,ab. | 4154 |
| 49 | (infliximab or Remicade or Remsima or Inflectra or Zessly or Flixabi or adalimumab or Humira or Imraldi or Amgevita or Hulio or vedolizumab or Entyvio or ustekinumab or Stelara).ti,ab. | 15559 |
| 50 | top-down.mp. | 13641 |
| 51 | top down.mp. | 13641 |
| 52 | step-up.mp. | 2492 |
| 53 | step up.mp. | 2492 |
| 54 | or/35-53 | 344592 |
| 55 | 7 and 54 | 13382 |
| 56 | exp Economics, Nursing/ or exp Economics, Pharmaceutical/ or exp Economics, Medical/ or exp Economics, Hospital/ | 43836 |
| 57 | Economics/ | 27043 |
| 58 | exp "Costs and Cost Analysis"/ | 225181 |
| 59 | exp "Fees and Charges"/ | 29739 |
| 60 | exp Budgets/ | 13513 |
| 61 | (economic\* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\* or pharmaco-economic\* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti,kf. | 213256 |
| 62 | (economic\* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\* or pharmaco-economic\* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2 | 263695 |
| 63 | (cost\* adj2 (effective\* or utilit\* or benefit\* or minimi\* or analy\* or outcome or outcomes)).ab,kf. | 147684 |
| 64 | (value adj2 (money or monetary)).ti,ab,kf. | 2192 |
| 65 | exp Models, Economic/ | 14158 |
| 66 | economic model\*.ab,kf. | 3037 |
| 67 | markov chains/ | 13431 |
| 68 | markov.ti,ab,kf. | 20502 |
| 69 | monte carlo method/ | 26768 |
| 70 | monte carlo.ti,ab,kf. | 45800 |
| 71 | exp Decision Trees/ or exp Decision Theory/ | 11468 |
| 72 | (decision\* adj2 (tree\* or analy\* or model\*)).ti,ab,kf. | 21223 |
| 73 | or/56-72 | 665817 |
| 74 | 7 and 73 | 1542 |
| 75 | 34 and 73 | 13 |
| 76 | 54 and 74 | 412 |
| 77 | letter.pt. | 1029243 |
| 78 | editorial.pt. | 492302 |
| 79 | historical article.pt. | 351921 |
| 80 | comment.pt. | 777323 |
| 81 | case reports.pt. | 2023130 |
| 82 | or/77-81 | 3878097 |
| 83 | 75 not 82 | 13 |
| 84 | 76 not 82 | 387 |
| 85 | limit 83 to humans | 11 |
| 86 | limit 84 to humans | 311 |

Table 6. Cochrane search strategy to identify economic evaluations

|  |  |  |
| --- | --- | --- |
| Cochrane  Date of search 07/06/2019 | | |
| # | Terms | Hits |
| #1 | MeSH descriptor: [Crohn Disease] this term only | 1406 |
| #2 | Crohn\* | 5032 |
| #3 | Crohn\* near/2 (disease or syndrome) | 4482 |
| #4 | regional enteritis | 45 |
| #5 | MeSH descriptor: [Inflammatory Bowel Diseases] this term only | 436 |
| #6 | inflammatory bowel disease\* or IBD | 7938 |
| #7 | #1 or #2 or #3 or #4 or #5 or #6 | 10448 |
| #8 | MeSH descriptor: [CD8-Positive T-Lymphocytes] this term only | 502 |
| #9 | MeSH descriptor: [CD8 Antigens] this term only | 71 |
| #10 | CD8 antigens or " CD8 antigen\*" or CD8\* or "CD 8\*" | 4571 |
| #11 | Regulatory t cells | 654 |
| #12 | PredictSure or PredictImmune | 0 |
| #13 | #8 or #9 or #10 or #11 or #12 | 5076 |
| #14 | MeSH descriptor: [Antibodies] this term only | 1353 |
| #15 | antibod\* | 39288 |
| #16 | glycan | 146 |
| #17 | antichitobioside carbohydrate antibod\* or ACCA or chitobioside | 18 |
| #18 | antilaminaribioside carbohydrate antibod\* or ALCA or laminaribioside | 6 |
| #19 | antimannobioside carbohydrate antibod\* or AMCA or mannobioside | 37 |
| #20 | anti-Saccharomyces cerevisiae antibod\* or ASCA or gASCA or mannan | 208 |
| #21 | anti-laminarin carbohydrate antibod\* or anti-L or laminarin | 1695 |
| #22 | neutrophil elastase degraded elastin or EL-NE | 386 |
| #23 | glycominds | 0 |
| #24 | IBDX | 0 |
| #25 | crohn\* disease prognos\* test | 50 |
| #26 | #14 or #15 | 39288 |
| #27 | #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 | 2404 |
| #28 | #26 and #27 | 347 |
| #29 | #7 and #13 | 65 |
| #30 | #7 and #28 | 44 |
| #31 | #29 or #30 | 105 |
| #32 | MeSH descriptor: [Prednisolone] this term only | 2693 |
| #33 | MeSH descriptor: [Prednisone] this term only | 3666 |
| #34 | MeSH descriptor: [Cortisone] this term only | 126 |
| #35 | MeSH descriptor: [Methylprednisolone] this term only | 2371 |
| #36 | MeSH descriptor: [Hydrocortisone] this term only | 5665 |
| #37 | (corticosteroid or prednisolone or prednisone or methylprednisolone or hydrocortisone or budesonide):ti,ab | 27102 |
| #38 | MeSH descriptor: [Mesalamine] this term only | 509 |
| #39 | MeSH descriptor: [Sulfasalazine] this term only | 448 |
| #40 | (mesalamine or sulfasalazine or "5-aminosalicylic\*" or "5-aminosalicylate\*" or "5-asa" or 5aminosalicylic\* or 5aminosalicyclate\* or 5asa or pentasa or mesalazine or mesalamine or asacol or sulfasalazine\* or salazopyrin\* or salazosulfapyridine\* or asulfidine\* or azulfadine\* or azulfidine\*):ti,ab | 2216 |
| #41 | MeSH descriptor: [Mercaptopurine] this term only | 252 |
| #42 | MeSH descriptor: [Azathioprine] this term only | 1166 |
| #43 | MeSH descriptor: [Methotrexate] this term only | 3755 |
| #44 | (immunosuppressant or immunomodulator or mercaptopurine or methotrexate or amethopterin or Otrexup or Rasuvo or Rheumatrex or Trexall or Maxtrex or Nordimet or Zlatal or Methofill or Metoject or Jylamvo or azathioprine or Imuran or Azapress or thiopurine):ti,ab | 12481 |
| #45 | (biologic or biologics or tumour necrosis factor alpha or TNF near/2 inhibitor\*):ti,ab | 9180 |
| #46 | (infliximab or Remicade or Remsima or Inflectra or Zessly or Flixabi or adalimumab or Humira or Imraldi or Amgevita or Hulio or vedolizumab or Entyvio or ustekinumab or Stelara):ti,ab | 4817 |
| #47 | top-down | 483 |
| #48 | top down | 483 |
| #49 | step-up | 731 |
| #50 | step up | 731 |
| #51 | #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 and #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 | 55540 |
| #52 | #7 and #51 | 3092 |
| #53 | MeSH descriptor: [Economics] 1 tree(s) exploded | 11682 |
| #54 | economic\* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\* or pharmaco-economic\* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed | 88865 |
| #55 | value near/2 (money or monetary) | 351 |
| #56 | cost\* near/2 (effective\* or utilit\* or benefit\* or minimi\* or analy\* or outcome or outcome) | 33230 |
| #57 | MeSH descriptor: [Models, Economic] this term only | 222 |
| #58 | MeSH descriptor: [Decision Trees] this term only | 157 |
| #59 | MeSH descriptor: [Probability] this term only | 3092 |
| #60 | markov or "monte carlo" or "economic model" | 2283 |
| #61 | decision\* near/2 (tree\* or analy\* or model\*) | 2352 |
| #62 | #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 | 94635 |
| #63 | #7 and #62 | 900 |
| #64 | #31 and #62 | 35 |
| #65 | #52 and #62 | 306 |

Table 7. CRD search strategy to identify economic evaluations

|  |  |  |
| --- | --- | --- |
| Centre for Reviews and Dissemination (CRD)  Date of search 07/06/2019 | | |
| # | Terms | Hits |
| 1 | MeSH DESCRIPTOR Crohn Disease EXPLODE ALL TREES | 220 |
| 2 | (crohn\*) | 374 |
| 3 | (Crohn\* NEAR2 (disease or syndrome) OR regional enteritis) | 356 |
| 4 | MeSH DESCRIPTOR Inflammatory Bowel Diseases EXPLODE ALL TREES | 456 |
| 5 | (inflammatory bowel disease\*) | 285 |
| 6 | (IBD) | 80 |
| 7 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 | 640 |
| 8 | MeSH DESCRIPTOR CD8-Positive T-Lymphocytes EXPLODE ALL TREES | 2 |
| 9 | MeSH DESCRIPTOR Antigens, CD8 EXPLODE ALL TREES | 0 |
| 10 | (CD8 antigen\* OR CD 8 antigen\* OR CD8\* OR CD 8\*) | 17 |
| 11 | MeSH DESCRIPTOR T-Lymphocytes, Regulatory EXPLODE ALL TREES | 2 |
| 12 | (Regulatory t cells) | 1 |
| 13 | (PredictSure OR PredictImmune) | 0 |
| 14 | #8 OR #9 OR #10 OR #11 OR #12 OR #13 | 19 |
| 15 | MeSH DESCRIPTOR Antibodies EXPLODE ALL TREES | 2097 |
| 16 | (antibod\*) | 2285 |
| 17 | (glycan) | 1 |
| 18 | (antichitobioside carbohydrate antibod\* OR ACCA OR chitobioside) | 0 |
| 19 | (antilaminaribioside carbohydrate antibod\* OR ALCA OR laminaribioside) | 0 |
| 20 | (antimannobioside carbohydrate antibod\* OR AMCA OR mannobioside) | 0 |
| 21 | (anti-Saccharomyces cerevisiae antibod\* OR ASCA OR gASCA OR mannan) | 11 |
| 22 | (anti-laminarin carbohydrate antibod\* OR anti-L OR laminarin) | 0 |
| 23 | (neutrophil elastase degraded elastin OR EL-NE) | 0 |
| 24 | (glycominds) | 0 |
| 25 | (prognos\* test OR IBDX) | 5 |
| 26 | #15 OR #16 | 2578 |
| 27 | #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 | 17 |
| 28 | #26 AND #27 | 7 |
| 29 | #7 AND #14 | 1 |
| 30 | #7 AND #28 | 4 |
| 31 | #29 OR #30 | 5 |
| 32 | (\* in DARE) | 45418 |
| 33 | (\* in NHSEED) | 17613 |
| 34 | (\* in HTA) | 17351 |
| 35 | #31 AND #32 | 3 |
| 36 | #31 AND #33 | 1 |
| 37 | #31 AND #34 | 1 |
| 38 | MeSH DESCRIPTOR Economics EXPLODE ALL TREES | 17657 |
| 39 | MeSH DESCRIPTOR Economics, Hospital EXPLODE ALL TREES | 1247 |
| 40 | MeSH DESCRIPTOR Economics, Medical EXPLODE ALL TREES | 53 |
| 41 | MeSH DESCRIPTOR Economics, Nursing EXPLODE ALL TREES | 9 |
| 42 | MeSH DESCRIPTOR Economics, Pharmaceutical EXPLODE ALL TREES | 199 |
| 43 | MeSH DESCRIPTOR Budgets EXPLODE ALL TREES | 54 |
| 44 | MeSH DESCRIPTOR Markov Chains EXPLODE ALL TREES | 2056 |
| 45 | MeSH DESCRIPTOR Decision Trees EXPLODE ALL TREES | 864 |
| 46 | MeSH DESCRIPTOR Decision Theory EXPLODE ALL TREES | 873 |
| 47 | MeSH DESCRIPTOR Probability EXPLODE ALL TREES | 10018 |
| 48 | MeSH DESCRIPTOR Costs and Cost Analysis EXPLODE ALL TREES | 17164 |
| 49 | (economic\* OR cost OR costs OR costly OR costing OR price OR prices OR pricing OR pharmacoeconomic\* OR pharmaco-economic\* OR expenditure OR expenditures OR expense OR expenses OR financial OR finance OR finances OR financed) | 26785 |
| 50 | (cost\* NEAR2 (effective\* OR utilit\* OR benefit\* OR minimi\* OR analy\* OR outcome OR outcomes)) | 20789 |
| 51 | (Markov OR economic model OR monte carlo) | 3877 |
| 52 | (decision\* NEAR2 (tree\* OR analy\* OR model\*)) | 3590 |
| 53 | #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 | 32706 |
| 54 | #7 AND #53 | 260 |
| 55 | #32 AND #54 | 108 |
| 56 | #33 AND #54 | 121 |
| 57 | #34 AND #54 | 31 |
| 58 | MeSH DESCRIPTOR Prednisolone EXPLODE ALL TREES | 97 |
| 59 | MeSH DESCRIPTOR Prednisone EXPLODE ALL TREES | 86 |
| 60 | MeSH DESCRIPTOR Cortisone EXPLODE ALL TREES | 1 |
| 61 | MeSH DESCRIPTOR Methylprednisolone EXPLODE ALL TREES | 43 |
| 62 | MeSH DESCRIPTOR Hydrocortisone EXPLODE ALL TREES | 25 |
| 63 | (corticosteroid OR prednisolone OR prednisone OR methylprednisolone OR hydrocortisone OR budesonide) | 1068 |
| 64 | MeSH DESCRIPTOR Mesalamine EXPLODE ALL TREES | 46 |
| 65 | MeSH DESCRIPTOR 6-Mercaptopurine EXPLODE ALL TREES | 80 |
| 66 | MeSH DESCRIPTOR Sulfasalazine EXPLODE ALL TREES | 18 |
| 67 | (mesalamine OR sulfasalazine OR "5-aminosalicylic\*" OR "5-aminosalicylate\*" OR "5-asa" OR 5aminosalicylic\* OR 5aminosalicyclate\* OR 5asa OR pentasa OR mesalazine OR mesalamine OR asacol OR sulfasalazine\* OR salazopyrin\* OR salazosulfapyridine\* OR asulfidine\* OR azulfadine\* OR azulfidine\*) | 142 |
| 68 | MeSH DESCRIPTOR Azathioprine EXPLODE ALL TREES | 73 |
| 69 | MeSH DESCRIPTOR Methotrexate EXPLODE ALL TREES | 176 |
| 70 | (immunosuppressant OR immunomodulator OR mercaptopurine OR methotrexate OR amethopterin OR Otrexup OR Rasuvo OR Rheumatrex OR Trexall OR Maxtrex OR Nordimet OR Zlatal OR Methofill OR Metoject OR Jylamvo OR azathioprine OR Imuran OR Azapress OR thiopurine) | 644 |
| 71 | (biologic OR biologics OR tumour necrosis factor alpha OR TNF NEAR2 inhibitor\*) | 308 |
| 72 | (infliximab OR Remicade OR Remsima OR Inflectra OR Zessly OR Flixabi OR adalimumab OR Humira OR Imraldi OR Amgevita OR Hulio OR vedolizumab OR Entyvio OR ustekinumab OR Stelara) | 438 |
| 73 | (top-down) | 37 |
| 74 | (top down) | 37 |
| 75 | (step-up) | 28 |
| 76 | (step up) | 28 |
| 77 | #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 | 2147 |
| 78 | #54 AND #77 | 120 |
| 79 | #55 AND #77 | 49 |
| 80 | #56 AND #77 | 60 |
| 81 | #57 AND #77 | 11 |

Table 8. EMBASE search strategy to identify studies on health-related quality of life

|  |  |  |
| --- | --- | --- |
| Embase <1974 to 2019 July 09>  Date of search 25/07/2019 | | |
| # | Terms | Hits |
| 1 | Crohn disease/ | 83044 |
| 2 | Crohn\*.mp. | 95973 |
| 3 | ((Crohn$ adj2 (disease or syndrome)) or regional enteritis).tw. | 69843 |
| 4 | inflammatory bowel disease/ | 27738 |
| 5 | IBD.mp. | 47446 |
| 6 | Inflammatory bowel disease\*.mp. | 80993 |
| 7 | or/1-6 | 145131 |
| 8 | exp quality adjusted life year/ | 24118 |
| 9 | (qaly$ or qald$ or qale$ or qtime$).ti,ab,kw. | 18449 |
| 10 | (quality adjusted or adjusted life year$).ti,ab,kw. | 22397 |
| 11 | disability adjusted life.ti,ab,kw. | 3630 |
| 12 | daly$1.ti,ab,kw. | 3588 |
| 13 | ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kw. | 1051 |
| 14 | (multiattribute$ or multi attribute$).ti,ab,kw. | 1079 |
| 15 | (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$ or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or status)).ti,ab,kw. | 47492 |
| 16 | utility.ab. /freq=2 | 24677 |
| 17 | utilities.ti,ab,kw. | 10761 |
| 18 | disutili$.ti,ab,kw. | 845 |
| 19 | (HSUV or HSUVs).ti,ab,kw. | 100 |
| 20 | health$1 year$1 equivalent$1.ti,ab,kw. | 44 |
| 21 | (hye or hyes).ti,ab,kw. | 130 |
| 22 | (hui or hui1 or hui2 or hui3).ti,ab,kw. | 2108 |
| 23 | (illness state$1 or health state$1).ti,ab,kw. | 10420 |
| 24 | (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or euroqual5d or euroqol5d).ti,ab,kw. | 18050 |
| 25 | (short form$ or shortform$).ti,ab,kw. | 41624 |
| 26 | (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kw. | 35765 |
| 27 | (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kw. | 4185 |
| 28 | (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kw. | 7524 |
| 29 | (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kw. | 47 |
| 30 | (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kw. | 328 |
| 31 | (15D or 15-D or 15 dimension).ti,ab,kw. | 6267 |
| 32 | (standard gamble$ or sg).ti,ab,kw. | 14405 |
| 33 | (time trade off$1 or time tradeoff$1 or tto or timetradeoff $1).ti,ab,kw. | 2609 |
| 34 | or/8-33 | 197191 |
| 35 | 7 and 34 | 1781 |
| 36 | letter.pt. | 1074956 |
| 37 | editorial.pt. | 623536 |
| 38 | note.pt. | 761313 |
| 39 | 36 or 37 or 38 | 2459805 |
| 40 | 35 not 39 | 1765 |

Table 9. MEDLINE search strategy to identify studies on health-related quality of life

|  |  |  |
| --- | --- | --- |
| Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to July 08, 2019>  Date of search 10/07/2019 | | |
| # | Terms | Hits |
| 1 | Crohn Disease/ | 37301 |
| 2 | Crohn\*.mp. | 53410 |
| 3 | ((Crohn$ adj2 (disease or syndrome)) or regional enteritis).tw. | 43196 |
| 4 | inflammatory bowel diseases/ | 20297 |
| 5 | IBD.mp. | 22666 |
| 6 | Inflammatory bowel disease\*.mp. | 48463 |
| 7 | or/1-6 | 85061 |
| 8 | exp Quality-Adjusted Life Years/ | 11153 |
| 9 | "Value of Life"/ | 5652 |
| 10 | (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. | 9753 |
| 11 | (quality adjusted or adjusted life year$).ti,ab,kf. | 15185 |
| 12 | disability adjusted life.ti,ab,kf. | 2961 |
| 13 | daly$1.ti,ab,kf. | 2647 |
| 14 | ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kf. | 654 |
| 15 | (multiattribute$ or multi attribute$).ti,ab,kf. | 835 |
| 16 | (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$ or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or status)).ti,ab,kf. | 30914 |
| 17 | utility.ab. /freq=2 | 15905 |
| 18 | utilities.ti,ab,kf. | 6591 |
| 19 | disutili$.ti,ab,kf. | 431 |
| 20 | (HSUV or HSUVs).ti,ab,kf. | 60 |
| 21 | health$1 year$1 equivalent$1.ti,ab,kf. | 40 |
| 22 | (hye or hyes).ti,ab,kf. | 66 |
| 23 | (hui or hui1 or hui2 or hui3).ti,ab,kf. | 1392 |
| 24 | (illness state$1 or health state$1).ti,ab,kf. | 6021 |
| 25 | (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or euroqual5d or euroqol5d).ti,ab,kf. | 9651 |
| 26 | (short form$ or shortform$).ti,ab,kf. | 30596 |
| 27 | (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. | 20791 |
| 28 | (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kf. | 3059 |
| 29 | (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. | 4303 |
| 30 | (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kf. | 27 |
| 31 | (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kf. | 330 |
| 32 | (15D or 15-D or 15 dimension).ti,ab,kf. | 4982 |
| 33 | (standard gamble$ or sg).ti,ab,kf. | 9836 |
| 34 | (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. | 1800 |
| 35 | or/8-34 | 133401 |
| 36 | 7 and 35 | 714 |
| 37 | letter.pt. | 1033774 |
| 38 | editorial.pt. | 495816 |
| 39 | historical article.pt. | 352651 |
| 40 | comment.pt. | 785307 |
| 41 | case reports.pt. | 2030156 |
| 42 | or/37-41 | 3896584 |
| 43 | 36 not 42 | 701 |
| 44 | limit 43 to humans | 575 |

Table 10. Cochrane search strategy to identify studies on health-related quality of life

|  |  |  |
| --- | --- | --- |
| Cochrane  Date of search 09/07/2019 | | |
| # | Terms | Hits |
| #1 | MeSH descriptor: [Crohn Disease] this term only | 1410 |
| #2 | Crohn\* | 5065 |
| #3 | Crohn\* near/2 (disease or syndrome) | 4514 |
| #4 | regional enteritis :ti,ab,kw | 29 |
| #5 | MeSH descriptor: [Inflammatory Bowel Diseases] this term only | 2911 |
| #6 | inflammatory bowel disease\* or IBD | 7989 |
| #7 | #1 or #2 or #3 or #4 or #5 or #6 | 10940 |
| #8 | MeSH descriptor: [Quality-Adjusted Life Years] explode all trees | 1125 |
| #9 | ("quality-adjusted life year\*" or QALY or QALYs or "quality adjusted life year\*"):ti,ab,kw | 4129 |
| #10 | ("quality near/2 life" or QOL):ti,ab,kw | 16848 |
| #11 | ("disability-adjusted life year\*" or DALY or DALYs or "disability adjusted life years\*"):ti,ab,kw | 214 |
| #12 | (HRQL or HRQOL):ti,ab,kw | 5525 |
| #13 | (sf36 or sf-36 or "sf 36" or "short form 36" or "shortform 36" or "sf thirtysix" or "sf thirty six" or "shortform thirtysix" or "shortform thirty six" or "short form thirty six" or "short form thirtysix" or "short form thirty six"):ti,ab,kw | 11476 |
| #14 | (sf6 or "sf 6" or "sf-6" or "short form 6" or "shortform 6" or "sf six" or sfsix or "shortform six" or "short form six"):ti,ab,kw | 179 |
| #15 | (sf6d or "sf 6d" or "sf-6d" or "short form 6d" or "shortform 6d" or "sf six dimension" or "short form six dimension"):ti,ab,kw | 285 |
| #16 | (sf12 or "sf 12" or sf-12 or "short form 12" or "shortform 12" or "sf twelve" or sftwelve or "shortform twelve" or "short form twelve"):ti,ab,kw | 2333 |
| #17 | (sf16 or "sf 16" or "sf-16" or "short form 16" or "shortform 16" or "sf sixteen" or sfsixteen or "shortform sixteen" or "short form sixteen"):ti,ab,kw | 5 |
| #18 | (sf20 or "sf 20" or sf-20 or "short form 20" or "shortform 20" or "sf twenty" or sftwenty or "shortform twenty" or "short form twenty"):ti,ab,kw | 86 |
| #19 | (euroqol or "euro qol" or eq5d or "eq 5d" or eq-5d):ti,ab,kw | 7392 |
| #20 | (hye or hyes or "health\* year\* equivalent\*"):ti,ab,kw | 9 |
| #21 | ("standard gamble" or SG):ti,ab,kw | 1266 |
| #22 | ((quality near/3 wellbeing index) or QWB):ti,ab,kw | 226 |
| #23 | ("time trade off" or "time tradeoff" or TTO or "time trade-off"):ti,ab,kw | 540 |
| #24 | (utility near/3 value):ti,ab,kw | 119 |
| #25 | disutil\*:ti,ab,kw | 70 |
| #26 | ("health utilities index" or HUI):ti,ab,kw | 264 |
| #27 | {OR #8-#26} | 40751 |
| #28 | #7 and #27 | 646 |

Table 11. CRD search strategy to identify studies on health-related quality of life

|  |  |  |
| --- | --- | --- |
| Centre for Reviews and Dissemination (CRD)  Date of search 09/07/2019 | | |
| # | Terms | Hits |
| #1 | MeSH DESCRIPTOR Crohn Disease EXPLODE ALL TREES | 220 |
| #2 | (crohn\*) | 374 |
| #3 | (Crohn\* NEAR2 (disease or syndrome) OR regional enteritis) | 356 |
| #4 | MeSH DESCRIPTOR Inflammatory Bowel Diseases EXPLODE ALL TREES | 456 |
| #5 | (inflammatory bowel disease\*) | 285 |
| #6 | (IBD) | 80 |
| #7 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 | 640 |
| #8 | MeSH DESCRIPTOR Quality-Adjusted Life Years EXPLODE ALL TREES | 3547 |
| #9 | (quality-adjusted life year OR QALY or QALYs OR quality adjusted life year\*) | 5531 |
| #10 | (quality NEAR2 life OR QOL) | 11586 |
| #11 | (disability-adjusted life year\* OR DALY OR DALYs OR disability adjusted life years\*) | 226 |
| #12 | (HRQL OR HRQOL) | 198 |
| #13 | (sf36 OR sf-36 OR sf 36 OR short form 36 OR shortform 36 OR sf thirtysix OR sf thirty six OR shortform thirtysix OR shortform thirty six OR short form thirty six OR short form thirtysix OR short form thirty six) | 409 |
| #14 | (sf6 OR sf 6 OR sf-6 OR short form 6 OR shortform 6 OR sf six OR sfsix OR shortform six or short form six) | 6 |
| #15 | (sf6d OR sf 6d OR sf-6d OR short form 6d OR shortform 6d OR sf six dimension OR short form six dimension) | 57 |
| #16 | (sf12 OR sf 12 or sf-12 OR short form 12 or shortform 12 OR sf twelve OR sftwelve OR shortform twelve or short form twelve) | 60 |
| #17 | (sf16 OR sf 16 OR sf-16 OR short form 16 OR shortform 16 OR sf sixteen OR sfsixteen OR shortform sixteen OR short form sixteen) | 1 |
| #18 | (sf20 OR sf 20 OR sf-20 OR short form 20 OR shortform 20 OR sf twenty OR sftwenty OR shortform twenty OR short form twenty) | 4 |
| #19 | (euroqol OR euro qol OR eq5d OR eq 5d OR eq-5d) | 790 |
| #20 | (hye OR hyes OR health\* year\* equivalent\*) | 11 |
| #21 | (standard gamble OR SG) | 455 |
| #22 | (quality NEAR3 wellbeing index OR QWB) | 18 |
| #23 | (time trade off OR time tradeoff or TTO or time trade-off) | 375 |
| #24 | (utility NEAR3 value) | 151 |
| #25 | (disutil\*) | 184 |
| #26 | (health utilities index OR HUI) | 201 |
| #27 | #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 | 12314 |
| #28 | #7 AND #27 | 118 |